Lp(a): The Inherited Risk Worth Asking About

Knowing your cholesterol is not the same as knowing your Lp(a)

Lipoprotein(a), written Lp(a) and pronounced L-P-little-a, is a cholesterol-carrying particle whose level is largely inherited. A standard lipid panel can be reassuring without revealing whether Lp(a) is elevated.

The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood. The result belongs with the rest of the story—age, blood pressure, smoking, diabetes, kidney health, family and pregnancy history, menopause, symptoms, treatment, and sometimes plaque imaging. It is a risk-enhancing factor, not a diagnosis or a prediction of what will happen to one person.

The useful question is what the result would change

A high result may lead a qualified clinician to interpret overall cardiovascular risk differently or to pay closer attention to risk factors that can be treated. It does not prove that plaque is present, identify a blocked artery, or automatically determine medication.

Because Lp(a) is largely inherited, a result can also have implications for family conversations. That does not mean relatives should be frightened or tested without context. It means the result may be worth discussing with the clinician who knows the family history.

• Ask whether Lp(a) has already been measured; the units may be mg/dL or nmol/L.
• Ask how the result changes the interpretation of your overall risk, if at all.
• Ask which modifiable risks deserve first place now.

A failed drug trial does not make the measurement meaningless

On September 4, 2026, Novartis reported that the phase III Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular endpoint. The announcement was a top-line result; full data were still pending when this article was reviewed.

That finding complicates the treatment story. It does not erase the current guideline’s once-in-adulthood measurement recommendation or prove that every way of lowering Lp(a) will fail. It does mean headlines should not outrun the completed analysis.